Back to top

Oppenheimer Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)

Oppenheimer analyst Mazahir Alimohamed maintained a Buy rating on Tarsus Pharmaceuticals today and set a price target of $97.00. According to TipRa...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Tarsus Pharmaceuticals, Inc. (TARS)